Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

Business Leaders

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
HomeAll NewsMost read newsBusiness Leaders Biography
Summary 
David M. Mott is an American businessperson who founded MedImmune Ventures, Inc. and who has been the head of 18 different companies. Currently, he holds the position of Chairman of Mersana Therapeutics, Inc., Chairman of Epizyme, Inc., Chairman for Ardelyx, Inc., Chairman at Complexa, Inc., Chairman of Cydan II, Inc., Chairman for Cydan LLC (a subsidiary of Cydan II, Inc.), Chairman of Adaptimmune Therapeutics Plc, Chairman of Imara, Inc. and Chairman at Vtesse, Inc. Mr. Mott is also on the board of 5 other companies.

In the past Mr. Mott held the position of Chairman at Zyngenia, Inc., Chairman of Sagimet Biosciences, Inc., Executive Vice President for AstraZeneca Plc Vice Chairman, President & Chief Executive Officer at MedImmune LLC, President & Chief Executive Officer at MedImmune Ltd. and President for MedImmune Ventures, Inc. (which are all subsidiaries of AstraZeneca Plc), General Partner at New Enterprise Associates LLC, General Partner for NEA Management Co. LLC, Chairman of Conceptis Technologies, Inc., Chairman of Tesaro, Inc., Chairman-Supervisory Board for Prosensa Holding NV, Chairman at Adaptimmune Ltd., Vice President-Health Care Investment Banking at Smith Barney Harris Upham & Co., Inc. and VP-Health Care Investment Banking Group at Harris Upham & Co, Inc.

He received an undergraduate degree from Dartmouth College.


Current positions of David M. Mott 
NameTitle Since
Novavax, Inc.
(Biotechnology & Medical Research)
Independent Director 2020
Mersana Therapeutics, Inc.
(Biotechnology & Medical Research)
Chairman 2015
Adaptimmune Therapeutics plc
(Biotechnology & Medical Research)
Chairman 2017
Epizyme, Inc.
(Biotechnology & Medical Research)
Chairman 2016
Ardelyx, Inc.
(Biotechnology & Medical Research)
Chairman 2014
IMARA Inc.
(Biotechnology & Medical Research)
Chairman 2016
Cydan II, Inc. Chairman -
Cydan LLC Chairman -
Vtesse, Inc. Chairman -
Biotechnology Innovation Organization Director -
Complexa, Inc. Chairman -
NEA 14 GP Ltd. Director -
XTuit Pharmaceuticals, Inc. Director -
Biohealth Innovation, Inc. Director -


Holdings of David M. Mott 
NameEquities%Valuation
Novavax, Inc. (NVAX)
(Biotechnology & Medical Research)
64,9610.087%15,495,797 USD
Mersana Therapeutics, Inc. (MRSN)
(Biotechnology & Medical Research)
548,1940.76%7,636,342 USD
Epizyme, Inc. (EPZM)
(Biotechnology & Medical Research)
271,5040.27%1,400,961 USD
Ardelyx, Inc. (ARDX)
(Biotechnology & Medical Research)
417,2840.40%588,370 USD
Adaptimmune Therapeutics Plc00.0000%0 USD
IMARA Inc. (IMRA)
(Biotechnology & Medical Research)
00.0000%0 USD


David M. Mott: Personal Network 
Most Read News 
09/04BERNARD ARNAULT : There is no conflict with Arnault
RE
09/07GEORGE SOROS : Soros says BlackRock's China investments likely to lose money - WSJ
RE
09/14BRAD SMITH : Microsoft to buy back up to $60 billion in shares; names Brad Smith vice chair
RE
09/09FRANCESCO GAETANO CALTAGIRONE : Italy's Caltagirone ups Generali stake to just over 6%
RE
09/14CATHIE WOOD : ARK Invest's Wood expects market rotation back to growth stocks
RE
09/09ELON MUSK : Tesla's Musk asks staff to 'go super hardcore' to ensure decent Q3 delivery number
RE
09/13MARTIN SORRELL : Sorrell's S4 Capital raises annual profit outlook for a third time
RE
09/08ELON MUSK : Amazon.com goes for jugular in FCC spat with SpaceX's Musk
RE
09/08BILL GATES : Bill Gates' investment firm to take control of Four Seasons in $2.21 billion deal
RE
09/17STELIOS HAJI-IOANNOU : EasyJet shareholder Stelios Haji-Ioannou shuns rights issue -source
RE
More news


© 2021 People and Ownership :   
David M. Mott : Connections